Axsome Therapeutics (AXSM) Projected to Post Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is expected to be issuing its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $191.3340 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 8:00 AM ET.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $183.72 on Friday. Axsome Therapeutics has a 1 year low of $86.99 and a 1 year high of $191.50. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The firm has a 50 day moving average price of $173.88 and a 200 day moving average price of $144.15. The company has a market cap of $9.26 billion, a price-to-earnings ratio of -39.34, a PEG ratio of 11.86 and a beta of 0.40.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $225.00 price target on shares of Axsome Therapeutics in a report on Monday, January 5th. HC Wainwright lifted their target price on Axsome Therapeutics from $200.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. UBS Group boosted their price target on Axsome Therapeutics from $163.00 to $248.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Morgan Stanley lowered Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a research note on Thursday, January 8th. Finally, Robert W. Baird set a $209.00 price objective on Axsome Therapeutics in a research note on Tuesday, January 13th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $216.07.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 12,000 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the transaction, the chief financial officer owned 42,588 shares in the company, valued at $8,003,136.96. The trade was a 21.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the sale, the director directly owned 10,002 shares of the company’s stock, valued at $1,652,130.36. The trade was a 78.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 308,874 shares of company stock valued at $51,390,805. 22.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AXSM. Kemnay Advisory Services Inc. purchased a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $31,000. Ameriflex Group Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $37,000. Advisory Services Network LLC purchased a new stake in Axsome Therapeutics during the 3rd quarter worth $40,000. Strive Financial Group LLC acquired a new position in Axsome Therapeutics in the 4th quarter worth $62,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Axsome Therapeutics by 87.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 374 shares of the company’s stock worth $68,000 after buying an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.